Abstract

PHARMACOLOGICAL ACTIVITIES OF BLOOD CANCER – IT’S DIAGNOSIS AND TREATMENT: A REVIEW

Shivani R. Vyavahare* and Bhakti Rajendra Wagh

ABSTRACT

Blood cancer represents a large group of different malignancies. This group includes cancers of the bone marrow, blood, and lymphatic system, which includes lymph nodeslymphatic vessels, tonsils, thymus, spleen, and digestive tract lymphoid tissue. Leukemia and myeloma, which start in the bone marrow, and lymphoma, which starts in the lymphatic system, are the most common types of blood cancer. What causes these cancers is not known. As leukemia and myeloma grow within the bone marrow, they can interfere with the bone marrow’s ability to produce normal blood cells, including white blood cells, red blood cells, and platelets. This can cause frequent infections, anemia, and easy bruising. Lymphomas, which most typically appear as enlargement of the lymph nodes, can also interfere with the body’s ability to fight infections. Additionally, myelomas generate a substance that weakens bones, and produce abnormal proteins that can cause symptoms in other parts of the body. Treatment of blood cancers has
undergone substantial improvements, resulting in increased rates of remission and survival. Remission occurs when there is no sign of cancer. Today in the United States, almost 1 million people are alive with, or in remission from, blood cancer. People who have blood cancer can have problems with bleeding and serious infections.

Keywords: Myelodysplastic syndromes chemotherapy, radiotherapy, Mitochondria DNA, Immunotherapy.